Keyword: Eli Lilly

A "multi-omic" analysis of more than 900 donor brains linked the amount of herpes virus in a person's brain to the presence of Alzheimer's markers.

Teva is ending a phase 3 trial of its CGRP blocker in chronic cluster headache after an analysis showed it was unlikely to meet its primary endpoint.

The partners stopped the two phase 3 studies after an independent interim analysis deemed they were destined to fail.

Alder BioPharmaceuticals poached Juno’s COO to lead the company, as it preps to submit its migraine treatment for FDA approval and heavy competition.

Transplanting pancreatic islets, along with a hydrogel that "trains" immune cells to accept them, could translate to a cure for Type 1 diabetes.

Just 48 hours after filing a $115 million IPO, Forty Seven unveiled the first data for its CD47 antibody at ASCO, pledging moves into phase 2 studies.

Early data from Zymeworks showed its lead bispecific antibody hit an overall response rate of 36%, as a single agent for a variety of HER2+ cancers.

The trial linked the JAK1 inhibitor to significant improvements in symptoms, laying the groundwork for further development in psoriatic arthritis.

Lilly’s oncology chief is retiring; a GSK vet is launching a Chinese public health startup; and Gilead’s R&D chief is going back to his roots.

Beta Bionics received FDA approval for home-use studies of a bionic pancreas that uses AI to vary insulin doses in Type 1 diabetes.